Research License. Subject to the terms and conditions of this Agreement, CRISPR hereby grants to [[Organization A:Organization]] and its Affiliates a non-exclusive, royalty-free, fully paid-up, worldwide license, with no right to grant sublicenses except to Subcontractors as provided in Section 2.7, to use the CRISPR Technology solely to perform the [[Organization A:Organization]] Activities during the Research Term.

Research License. Subject to the terms and conditions of this Agreement, Poseida hereby grants to Takeda a non-exclusive, royalty-free, worldwide, sublicensable (solely to its Affiliates and Third Parties who engage in research activities in collaboration with, or as a fee-for-service for, Takeda or any of its Affiliates) license under the Licensed IP to perform Takeda’s obligations under the Platform Evaluation Work Plan and Research Plans (including any additional activities assumed by Takeda pursuant to [Section 3.2(a)]).

Research Stage License. Roche hereby grants to Poseida, effective upon the Effective Date, a non-exclusive, non-transferable (except as permitted pursuant to [Section 17.3]), non-sublicensable, worldwide license under the Roche Background IP to perform the activities allocated to Poseida under the Initial Collaboration Research Plan during the Initial Collaboration Research Term (and if applicable, under the Additional Collaboration Research Plan during the Additional Collaboration Research Term) and Poseida’s Manufacturing obligations under [Section 5.2.1(a)].

Research and Manufacturing License. BMS hereby grants to MTEM a non-exclusive, fully paid-up, non-transferable (except as provided in [Section 13.1]) royalty-free license, with the right to grant sublicenses to Affiliates and permitted subcontractors, under the BMS Know-How and BMS Patents, ​, solely to perform MTEM’s obligations under the Research Plans and to Manufacture Licensed Development Candidates and Licensed Products in accordance with [Section 6.4.1].

Research License to iTeos. During the Research Term and Evaluation Term for each Research Program, [[Adimab:Organization]] hereby grants iTeos a non-exclusive, non-sublicensable license under the [[Adimab:Organization]] Platform Patents and Program Antibody Patents to perform research in the Field for the purposes of performing iTeos’s responsibilities under this Agreement and each Research Plan hereunder and to evaluate Program Antibodies for purposes of determining whether to exercise an Option. For clarity, the license to iTeos excludes the right to # discover, optimize, or otherwise generate Program-Benefited Antibodies, # discover or optimize other antibodies using the [[Adimab:Organization]] Materials, [[Adimab:Organization]] Platform Technology or [[Adimab:Organization]] Platform Technology Improvements, or # use Program Antibodies or [[Adimab:Organization]] Materials to # screen for other antibodies’ activity vis-a-vis the applicable Target or # design other antibodies (in each case, other than Program-Benefited Antibodies that will be milestone- and royalty-bearing to [[Adimab:Organization]] under this Agreement).

Research Stage License. Poseida hereby grants to Roche, effective upon the Effective Date, a non-exclusive, non-transferable (except as permitted pursuant to [Section 17.3]), worldwide license, including the right to sublicense through multiple tiers (in accordance with [Section 6.8]), under the Poseida Background IP solely to perform the activities allocated to Roche under the Initial Collaboration Research Plan during the Initial Collaboration Research Term (and if applicable, under the Additional Collaboration Research Plan during the Additional Collaboration Research Term).

Research License. Subject to the terms and conditions of this Agreement, during the Antigen Research Term for each Janssen Antigen, Fate hereby grants to Janssen a non-exclusive, royalty-free, non-transferable (except as permitted under [Section 17.4]) license in the Territory, with the right to grant sublicenses solely in accordance with Section 5.5.1, under Fate Research Patents and Fate Research Know-How solely as and to the extent necessary to enable Janssen to perform Janssen’s obligations as set forth under the Research Plan for each Janssen Antigen (including through the engagement of subcontractors in accordance with [Section 3.9]) (the “Research License”). For the avoidance of doubt, # except as otherwise expressly set forth in the Research Plan for the Janssen Antigen, Janssen shall not conduct any Development, Manufacture, or Commercialization of any Collaboration Candidate, or any product containing any Collaboration Candidate, unless and until such time as Janssen exercises its Commercial Option in accordance with Section 4.3 for such Collaboration Candidate and such Collaboration Candidate becomes a Licensed Collaboration Candidate, # if Janssen does not exercise its Commercial Option with respect to a Collaboration Candidate during the applicable Commercial Option Term in accordance with Section 4.3, the Research License granted to Janssen under this [Section 5.1.1] shall expire with respect to such Collaboration Candidate upon expiration of such Commercial Option Term; and # if Janssen terminates this Agreement under [Section 15.3] with respect to any particular Janssen Antigen during the Antigen Research Term, then the Research License granted to Janssen under this [Section 5.1.1] with respect to such Janssen Antigen shall terminate in accordance with [Section 15.7.1(a)] and this Agreement shall terminate with respect to such Janssen Antigen in accordance with [Section 15.3]. During the Antigen Research Term for each Janssen Antigen, Fate shall not enter into an agreement with a Third Party relating to, or otherwise grant any rights to any Third Party with respect to, any CAR Cell Construct expressing a CAR Directed to such Janssen Antigen.

Research License. Subject to the terms and conditions of this Agreement, Sangamo hereby grants to Kite a royalty-free, non-exclusive license, with the right to grant sublicenses only to its Affiliates and subcontractors, under the Sangamo Technology, Joint Patents and Joint Inventions, solely to conduct those research activities allocated to Kite in the Research Plans.

Research License. Subject to the terms and conditions of this Agreement, during the Antigen Research Term for each Janssen Antigen, Janssen hereby grants to Fate a non-exclusive, royalty-free, non-transferable (except as permitted under [Section 17.4]) license in the Territory, with the right to grant sublicenses solely in accordance with Section 5.5.1, under Janssen Research Patents and Janssen Research Know-How solely as and to the extent necessary to enable Fate to perform Fate’s obligations as set forth under the Research Plan for each Janssen Antigen (including through the engagement of subcontractors in accordance with [Section 3.9]). For the avoidance of doubt, if Janssen does not exercise its Commercial Option with respect to any Collaboration Candidates under a Research Program during the applicable Commercial Option Term in accordance with Section 4.3, the research license granted to Fate under this Section 5.2 shall expire with respect to all such Collaboration Candidates under such Research Program upon expiration of such last-to-expire Commercial Option Term.

Research License. Subject to the terms and conditions of this Agreement, [[Organization A:Organization]] hereby grants to CRISPR a non-exclusive, royalty-free, fully paid-up, worldwide license, with no right to grant sublicenses except to Subcontractors as provided under section 2.7, to use the [[Organization A:Organization]] Technology solely to perform the CRISPR Activities during the Research Term.